Atlantic International Corp.

NASDAQ:ATLN

Medical - Diagnostics & Research

Healthcare
$0.90 -13.84%

-$0.10 today

Market cap
$73.17M
Beta
0.71
P/E (TTM)
-0.6
EPS (TTM)
-$1.08
52W Low $0.60High $5.25

Volume 18.56M

Average 0.44M

ATLN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Atlantic International Corp.NASDAQ: ATLN

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development remains negative

Q4 FY2025 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMDec 2025
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How ATLN compares with its peers on the latest reported figures

  • ATLN's LTM Dec 2025 research & development of $0 is the lowest of the 8 companies compared; the peer median is $17.59M.
  • Research & development amounts to 0.0% of revenue for ATLN, versus a peer median of 902.4%.
ATLN Competitors Peer median
Research & Development for ATLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTXNkarta, Inc.LTM Mar 2026$88.91M -7.1%-0.2%—
AVRAnteris Technologies Global Corp.LTM Mar 2026$70.12M +24.4%+57.8%3788.3%
PEPGPepGen Inc.LTM Mar 2026$58.35M -32.7%+9.5%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$17.59M +68.3%+29.6%902.4%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M +5.5%-23.1%928.4%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M -47.4%-11.0%4.2%
PREPrenetics Global LimitedLTM Mar 2026$4.57M -56.9%-5.0%4.0%
ATLNAtlantic International Corp.LTM Dec 2025$0 ——0.0%
Peer median (excluding ATLN) $17.59M-7.1%-0.2%902.4%

Competitors are the stored peer set for ATLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue425.03M441.54M401.37M442.61M435.88M
Cost of Revenue370.62M387.34M354.5M395.43M389.89M
Gross Profit54.41M54.21M46.88M47.18M45.99M
Gross Margin12.8%12.3%11.7%10.7%10.6%
Research & Development00000
Selling, General & Admin42.18M42.27M45.44M64.02M91.29M
Operating Expenses90.14M48.23M50.33M69.01M96.22M
Depreciation & Amortization4.11M5.07M5.04M4.99M6.59M
EBITDA12.18M11.94M1.44M(113.1M)(43.64M)
EBITDA Margin2.9%2.7%0.4%-25.6%-10.0%
Operating Income(35.73M)5.98M(3.45M)(21.83M)(50.23M)
Operating Margin-8.4%1.4%-0.9%-4.9%-11.5%
Interest Income36.46K44.88K000
Interest Expense208.29K90.75K17.54M12M9.16M
Other Income / Expenses(3.73M)(8.39M)(17.73M)(108.27M)(9.16M)
Income Before Tax(39.46M)(2.41M)(21.18M)(130.1M)(59.4M)
Pre-Tax Margin-9.3%-0.5%-5.3%-29.4%-13.6%
Income Tax Expense1.33M808.43K(5.93M)5.38M33.99K
Net Income(40.8M)(3.22M)(15.25M)(135.48M)(59.43M)
Net Margin-9.6%-0.7%-3.8%-30.6%-13.6%
EPS (Basic)(0.17)(0.19)(0.60)(3.68)(1.08)
EPS (Diluted)(0.17)(0.17)(0.60)(3.68)(1.08)
Weighted Avg Shares21.69M21.69M25.42M36.78M54.85M
Weighted Avg Shares (Diluted)21.69M24.14M25.42M36.78M54.85M

Atlantic International Corp.

NASDAQ:ATLN

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.